FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Ovarian CancerNon-small Cell Lung Cancer
Interventions
DRUG

TUB-040

A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle

Trial Locations (12)

3000

RECRUITING

UZ Leuven, Leuven

10117

RECRUITING

Charité Universitätsmedizin Berlin, Berlin

22031

RECRUITING

Next Oncology Virginia, Fairfax

28027

RECRUITING

Clínica universidad de Navarra, Madrid

28223

RECRUITING

NEXT Oncology Madrid, Madrid

45219

RECRUITING

Christ Hospital, Cincinnati

50937

RECRUITING

University Hospital Cologne Department of Internal Medicine I, Cologne

73104

RECRUITING

OU Health Stephenson Cancer Center, Oklahoma City

75039

RECRUITING

Next Oncology Dallas, Irving

Unknown

RECRUITING

Arensia Exploratory Medicine, Cluj-Napoca

RECRUITING

Arensia Exploratory Medicine, Kyiv

SE1 9RT

RECRUITING

Guy's Hospital, London

All Listed Sponsors
lead

Tubulis GmbH

INDUSTRY